Penumbra (PEN) Stock Price, News & Analysis

Company Overview

Penumbra, Inc. is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases. The company also offers embolization coil systems and flow-diversion devices for the treatment of cerebral aneurysms and vascular lesions. In its peripheral vascular line, Penumbra markets aspiration thrombectomy systems and small-vessel clot retrieval tools designed for limb salvage and treatment of pulmonary embolism.

Founded in 2004 by engineer Arani Bose, Penumbra launched its first commercial thrombectomy product in 2007 and has since expanded into new geographies and indications. The company maintains its headquarters in Alameda, California, with additional operations in Europe and Asia Pacific. Over the years, Penumbra has invested in R&D facilities and regulatory approvals to support product launches across more than 100 countries.

Under the leadership of President and Chief Executive Officer Adam Elsesser, Penumbra continues to advance its pipeline of next-generation devices, focusing on catheter design, clot visualization and real-time feedback technologies. The company collaborates with academic institutions and clinical specialists to refine procedural techniques and drive evidence generation in stroke and vascular care.

Key Stats

• Today's Range: $320.40 to $322.09
• 50-Day Range: $318.46 to $335.05
• 52-Week Range: $221.26 to $362.41
• Volume: 441,272 shs
• Average Volume: 791,969 shs
• Market Capitalization: $12.62 billion
• P/E Ratio: 73.95
• Dividend Yield: N/A
• Price Target: $361.33
• Consensus Rating: Hold

Penumbra Stock Analysis - MarketRank™

Penumbra scored higher than 39% of companies evaluated by MarketBeat, and ranked 662nd out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Hold

Consensus Rating

Penumbra has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on no strong buy ratings, 3 buy ratings, 14 hold ratings, and no sell ratings.

Upside Potential

Penumbra has a consensus price target of $361.33, representing about 12.6% upside from its current price of $320.94.

Amount of Analyst Coverage

Penumbra has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 24.61%

Earnings Growth

Earnings for Penumbra are expected to grow by 24.61% in the coming year, from $5.08 to $6.33 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Penumbra is 73.95, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.77.

Price to Earnings Ratio vs. Sector

The P/E ratio of Penumbra is 73.95, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.57.

Price to Earnings Growth Ratio

Penumbra has a PEG Ratio of 1.96. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Penumbra has a P/B Ratio of 8.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.02% of the float of Penumbra has been sold short.

Short Interest Ratio / Days to Cover

Penumbra has a short interest ratio ("days to cover") of 4.65.

Change versus previous month

Short interest in Penumbra has recently increased by 1.02%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Penumbra does not currently pay a dividend.

Dividend Growth

Penumbra does not have a long track record of dividend growth.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: 0.51

News Sentiment

Penumbra has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Penumbra this week, compared to 5 articles on an average week.

Search Interest

Only 1 people have searched for PEN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Penumbra insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $32,822.00 in company stock.

Percentage Held by Insiders

2.90% of the stock of Penumbra is held by insiders.

Percentage Held by Institutions

88.88% of the stock of Penumbra is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/06/2026
• Today: 6/09/2026
• Next Earnings (Estimated): 8/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:PEN
• CIK: 1321732
• Web: www.penumbrainc.com
• Phone: (510) 748-3200
• Fax: 510-748-3232
• Employees: 4,700
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Penumbra: $361.33
• High Price Target: $388.00
• Low Price Target: $266.00
• Potential Upside/Downside: +12.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.18
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): $4.34
• Trailing P/E Ratio: 73.95
• Forward P/E Ratio: 63.18
• P/E Growth: 1.96
• Net Income: $177.69 million
• Net Margins: 11.76%
• Pretax Margin: 13.96%
• Return on Equity: 10.87%
• Return on Assets: 8.45%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 6.02
• Quick Ratio: 3.95

Sales & Book Value

• Annual Sales: $1.40 billion
• Price / Sales: 8.99
• Cash Flow: $4.30 per share
• Price / Cash Flow: 74.56
• Book Value: $36.45 per share
• Price / Book: 8.80

Miscellaneous

• Outstanding Shares: 39,330,000
• Free Float: 38,190,000
• Market Cap: $12.62 billion
• Optionable: Optionable
• Beta: 0.71